Analysts are signaling optimism in the healthcare sector, with bullish ratings issued for Palisade Bio (PALI) and Centessa Pharmaceuticals (CNTA).
Holiday Savings on TipRanks Research
Palisade Bio (PALI)
Piper Sandler initiated coverage of Palisade Bio on December 29, assigning a Buy rating and a $25.00 price target. Shares of the company closed last Wednesday at $2.35.
According to TipRanks.com, analyst Yasmeen Rahimi boasts a 5-star rating with an average return of 25.7% and a 46.5% success rate. Rahimi’s coverage focuses on healthcare stocks including Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines.
Palisade Bio currently has a Moderate Buy consensus rating from analysts, with an average price target of $16.50.
See the top stocks recommended by analysts >>
Centessa Pharmaceuticals (CNTA)
Yesterday, Rudy Li from Chardan Capital initiated coverage of Centessa Pharmaceuticals with a Buy rating and a $30.00 price target. The company’s shares closed last Wednesday at $25.01.
TipRanks.com data shows Li is a 5-star analyst with an average return of 66.1% and a 57.1% success rate, specializing in healthcare stocks like Praxis Precision Medicines, Alto Neuroscience, Inc., and Xenon.
Centessa Pharmaceuticals currently holds a Strong Buy consensus rating from analysts, with an average price target of $39.00, representing a potential 57.1% upside. Wells Fargo also maintained a Buy rating on the stock on December 17, setting a $35.00 price target.
